Centrexion Therapeutics Inc. CEO Jeffrey Kindler told BioWorld Today his firm owns “one of the largest pipelines, if not the largest, in non-addictive chronic pain treatment,” thanks to the acquisition of three oral analgesic prospects from Boehringer Ingelheim GmbH (BI).